title: Novel agents targeting nitric oxide.
abstract: Nitric oxide (NO) is a soluble gas continuously synthesized from the amino acid L-arginine in endothelial cells by the constitutive calcium-calmodulin-dependent enzyme nitric oxide synthase (NOS). Endothelial dysfunction has been identified as a major mechanism involved in all the stages of atherogenesis. Evaluation of endothelial function seems to have a predictive role in humans, and therapeutic interventions improving nitric oxide bioavailability in the vasculature, may improve the long-term outcome in healthy individuals, high-risk subjects or patients with advanced atherosclerosis. Several therapeutic strategies (including statins, angiotensin converting enzyme inhibitors/angiotensin receptors blockers, insulin sensitizers, antioxidant compounds) are now available, targeting both the synthesis and oxidative inactivation of NO in human vasculature, reversing in that way endothelial dysfunction which is enhanced by the release of nitric oxide from the endothelium.
authors: 1st Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, Greece. kampoliannamaria@yahoo.gr
authors: Anna-Maria
authors: AM
authors: Kampoli
authors: Dimitris
authors: D
authors: Tousoulis
authors: Costas
authors: C
authors: Tentolouris
authors: Christodoulos
authors: C
authors: Stefanadis
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D009569:Nitric Oxide / Q000378:metabolism* / Q000502:physiology; D014652:Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009569:Nitric Oxide